NASDAQ:QUCY Mainz Biomed (QUCY) Stock Price, News & Analysis $1.59 +0.07 (+4.61%) As of 09/4/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsSEC Filings About Mainz Biomed Stock (NASDAQ:QUCY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Mainz Biomed alerts:Sign Up Key Stats Today's Range$1.51▼$1.6350-Day Range$1.06▼$1.6052-Week Range$0.30▼$4.93Volume1.17 million shsAverage Volume893,473 shsMarket Capitalization$23.31 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany. Read More Mainz Biomed Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks13th Percentile Overall ScoreQUCY MarketRank™: Mainz Biomed scored higher than 13% of companies evaluated by MarketBeat, and ranked 606th out of 662 stocks in the industrials sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.7 / 5Analyst RatingHold Consensus RatingMainz Biomed has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 strong buy rating, no buy ratings, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageMainz Biomed has only been the subject of 3 research reports in the past 90 days.Read more about Mainz Biomed's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Mainz Biomed are expected to grow in the coming year, from ($0.49) to ($0.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mainz Biomed is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mainz Biomed is -0.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMainz Biomed has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.37% of the float of Mainz Biomed has been sold short.Short Interest Ratio / Days to CoverMainz Biomed has a short interest ratio ("days to cover") of 2.75, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mainz Biomed has recently increased by 1.79%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMainz Biomed does not currently pay a dividend.Dividend GrowthMainz Biomed does not have a long track record of dividend growth. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 4 news articles for Mainz Biomed this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for QUCY on MarketBeat in the last 30 days. This is a decrease of -63% compared to the previous 30 days.MarketBeat Follows3 people have added Mainz Biomed to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Mainz Biomed insiders have not sold or bought any company stock.Percentage Held by Insiders3.10% of the stock of Mainz Biomed is held by insiders.Percentage Held by InstitutionsMainz Biomed has minimal institutional ownership at this time.Read more about Mainz Biomed's insider trading history. Receive QUCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mainz Biomed and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. QUCY Stock News HeadlinesQuantum Cyber NV (QUCY)September 4 at 2:59 PM | ru.investing.comQuantum Cyber Invites Qualified Foundries, and Prototype-Development Partners to Apply for Its Quantum-Photonic Antenna Manufacturing Program; Responses Due September 18, 2026September 4 at 7:30 AM | globenewswire.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country. | Banyan Hill Publishing (Ad)Quantum Cyber Appoints Tzvi Lev as Head of Sales, Middle East to Lead GCC Commercial Expansion of Its Autonomous Defense PlatformSeptember 2 at 7:30 AM | globenewswire.comQuantum Cyber Completes Purchase and Installation of 80-Unit 3D Printing Drone Production Farm at Its Bridgeport, Connecticut Manufacturing FacilityAugust 31, 2026 | globenewswire.comQuantum Cyber Appoints Veteran Distribution Executive Dennis Schnur as Head of U.S. Sales as Company Advances Toward Commercialization of Domestic Drone ProductionAugust 25, 2026 | globenewswire.comQuantum Cyber Rejects Threat of Future Publications from Short-Seller Adam Gefvert Demanding Withdrawal of $5.69 Million LawsuitAugust 20, 2026 | globenewswire.comQuantum Cyber to Participate in Invitation-Only 1640 Society Hamptons Family Office Wealth Forum 2026August 17, 2026 | globenewswire.comSee More Headlines QUCY Stock Analysis - Frequently Asked Questions How have QUCY shares performed this year? Mainz Biomed's stock was trading at $0.7374 on March 13, 2026. Since then, QUCY stock has increased by 115.6% and is now trading at $1.59. How do I buy shares of Mainz Biomed? Shares of QUCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today9/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 QUCY's financial health is in the Yellow zone, according to TradeSmith. QUCY has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorIndustrials Industry Aerospace & Defense Sub-IndustryAerospace & Defense Current SymbolNASDAQ:QUCY CIK1874252 Webmainzbiomed.com Phone49 6131 5542860FaxN/AEmployees30Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio5.56 Quick Ratio5.56 Sales & Book Value Annual Sales$540 thousand Price / Sales43.17 Cash FlowN/A Price / Cash FlowN/A Book Value$1.38 per share Price / Book1.15Miscellaneous Outstanding Shares14,660,000Free Float14,207,000Market Cap$23.31 million OptionableN/A Beta2.35 The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:QUCY) was last updated on 9/5/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mainz Biomed NV Please log in to your account or sign up in order to add this asset to your watchlist. Share Mainz Biomed With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
